Department of Clinical Laboratory, First Affiliated Hospital, Anhui Medical University, 218 Jixi Road, Hefei, Anhui, 230022, People's Republic of China.
Department of Clinical Laboratory, Fourth Affiliated Hospital, Anhui Medical University, 100 Huaihai Road, Hefei, Anhui, People's Republic of China.
BMC Immunol. 2021 Jun 27;22(1):40. doi: 10.1186/s12865-021-00436-6.
Pneumocystis pneumonia (PcP), which is caused by Pneumocystis carinii, is a life-threatening infection that affects immunocompromised individuals. Unfortunately, chemoprophylaxis and dapsone are only effective for half of the patients with PcP, indicating that additional preventive methods are needed. We predicated the pneumocystis surface protein A12 sequence 1-85 by DNAStar software and BepiPred, and identified it as a potential vaccine candidate by bioresearch.
We used recombinant A12 as antigen to immunized mice and detected serum titer of IgG, expression of inflammatory factors by EILSA, qRT-PCR and flow cytometry.
Our results showed that immunization with recombinant A12 increased the serum titer of IgG, promoted the secretion of T lymphocytes, increased the expression of inflammatory factors, and elevated lung inflammatory injury in mice.
Our findings suggest that A12 is a potential vaccine target for preventing Pneumocystis carinii. The evaluation of A12-elicited antibodies in the prevention of PcP in humans deserves further investigation.
由卡氏肺孢子虫引起的卡氏肺孢子虫肺炎（PcP）是一种危及生命的感染，影响免疫功能低下的个体。不幸的是，化学预防和氨苯砜仅对一半的 PcP 患者有效，这表明需要额外的预防方法。我们通过 DNAStar 软件和 BepiPred 预测了肺孢子虫表面蛋白 A12 序列 1-85，并通过生物研究将其鉴定为一种潜在的疫苗候选物。
我们使用重组 A12 作为抗原免疫小鼠，并通过 EILSA、qRT-PCR 和流式细胞术检测 IgG 血清滴度、炎症因子的表达。
我们的结果表明，用重组 A12 免疫可提高 IgG 血清滴度，促进 T 淋巴细胞的分泌，增加炎症因子的表达，并加重小鼠肺部炎症损伤。
我们的研究结果表明，A12 是预防卡氏肺孢子虫的潜在疫苗靶标。在人类中评估 A12 诱导的抗体在预防 PcP 中的作用值得进一步研究。
